{
  "label": "clinical_signal_03_ep_026",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:c8ec2a7b2e60743df8c142a1fb947c03f41df6d1885fabc02216a0cc7a001b94",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:55:40.337752",
  "content": "## 2024-08-26 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 234\n- Active: 220\n- Screen Failures Cumulative: 69\n- Withdrawals Cumulative: 14\n\n#### Sites\n- Site 01 Enrolled: 24\n- Site 01 Active: 23\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 22\n- Site 03 Active: 21\n- Site 03 Statin Concomitant: 7\n- Site 04 Enrolled: 16\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 5\n- Site 05 Enrolled: 19\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 6\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 25\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 8\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 19\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 16\n- Site 10 Active: 16\n- Site 10 Statin Concomitant: 5\n- Site 11 Enrolled: 22\n- Site 11 Active: 21\n- Site 11 Statin Concomitant: 6\n- Site 12 Enrolled: 17\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 148.8\n- ALT (U/L) Median: 148.6\n- AST (U/L) Mean: 104.7\n- AST (U/L) Median: 102.9\n- Bilirubin (mg/dL) Mean: 2.32\n- Bilirubin (mg/dL) Median: 2.32\n- ALP (U/L) Mean: 81.8\n- ALP (U/L) Median: 62.7\n- Creatinine (mg/dL) Mean: 1.01\n- Creatinine (mg/dL) Median: 0.89\n- BUN (mg/dL) Mean: 15.9\n- BUN (mg/dL) Median: 12.0\n- WBC (K) Mean: 6.1\n- WBC (K) Median: 6.5\n- Platelets (K) Mean: 260\n- Platelets (K) Median: 247\n\n#### Non-Statin Subgroup\n- N: 132\n- ALT (U/L) Mean: 31.3\n- ALT (U/L) Median: 31.2\n- AST (U/L) Mean: 29.1\n- AST (U/L) Median: 28.1\n- Bilirubin (mg/dL) Mean: 0.89\n- Bilirubin (mg/dL) Median: 0.87\n- ALP (U/L) Mean: 58.0\n- ALP (U/L) Median: 69.6\n- Creatinine (mg/dL) Mean: 1.0\n- Creatinine (mg/dL) Median: 0.91\n- BUN (mg/dL) Mean: 17.6\n- BUN (mg/dL) Median: 12.0\n- WBC (K) Mean: 7.5\n- WBC (K) Median: 5.9\n- Platelets (K) Mean: 232\n- Platelets (K) Median: 238\n\n### Adverse Events\n- AE ID: AE-0107, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0108, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0109, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0110, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 46\n- ACE Inhibitor Count: 28\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 37\n\n### Protocol Deviations\n- PD ID: PD-053, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_05\n- PD ID: PD-054, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_07\n- PD ID: PD-055, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_03\n\n### Investigator Notes\n- Study drug accountability reconciled, no discrepancies\n- All CRFs current through prior visit cycle\n- Protocol amendment v4.0 submitted to IRB: statin exclusion criterion added, CYP3A4 substrate screening required\n- In-vitro CYP3A4 Ki data received: LNS-4821 Ki = 0.8 uM, consistent with clinical DDI magnitude\n\n### Events\n- CRO quarterly oversight report submitted\n- Site 06 new coordinator onboarding completed\n- Investigator meeting minutes distributed\n- Protocol amendment v4.0 submitted to central IRB\n\n### Notes\n- Week 26: Protocol amendment v4.0 under IRB review/approval. Statin subjects transitioning.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_026",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-08-26T10:00:00",
    "phase": "root_cause",
    "signal_density": "high",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}